STOCK TITAN

AEON Biopharma (AEON) Stock News, Aug 2023-Mar 2024

AEON NYSE

AEON Biopharma develops ABP-450 (prabotulinumtoxinA) as a proposed biosimilar to BOTOX (onabotulinumtoxinA) for therapeutic indications. Company announcements focus on analytical similarity work, FDA biosimilar pathway interactions, scientific presentations, and the regulatory strategy supporting ABP-450 development.

Recurring AEON updates also address operating and financial results, liquidity and going-concern disclosures, shareholder meeting matters, inducement equity awards, executive and governance changes, capital-structure actions, and NYSE American continued-listing compliance.

Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.95%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.57%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.57%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.20%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.91%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.06%
Tags
none

FAQ

What is the current stock price of AEON Biopharma (AEON)?

AEON Biopharma (AEON) last closed at $0.1230.

What is the market cap of AEON Biopharma (AEON)?

The market cap of AEON Biopharma (AEON) is approximately $10.3M.